Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 23ME-01473 |
| Synonyms | |
| Therapy Description |
23ME-01473 is a monoclonal antibody that targets ULBP2, ULBP5, and ULBP6, potentially resulting in enhanced antitumor immune response and increased tumor cell killing (Cancer Res (2024) 84 (6_Supplement): 2375). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 23ME-01473 | 23ME01473|23ME 01473 | 23ME-01473 is a monoclonal antibody that targets ULBP2, ULBP5, and ULBP6, potentially resulting in enhanced antitumor immune response and increased tumor cell killing (Cancer Res (2024) 84 (6_Supplement): 2375). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06290388 | Phase Ib/II | 23ME-01473 | Study of 23ME-01473 in Patients With Advanced Solid Malignancies | Terminated | USA | 0 |